According to Zacks, “Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts, United States. “
Other equities analysts have also recently issued research reports about the stock. Chardan Capital reissued a “neutral” rating on shares of Evelo Biosciences in a research note on Thursday, September 19th. ValuEngine raised shares of Evelo Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Evelo Biosciences currently has an average rating of “Buy” and a consensus price target of $15.38.
Evelo Biosciences (NASDAQ:EVLO) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.67) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.67). On average, equities analysts predict that Evelo Biosciences will post -2.46 EPS for the current year.
Several institutional investors have recently made changes to their positions in EVLO. FMR LLC boosted its stake in shares of Evelo Biosciences by 0.6% in the 1st quarter. FMR LLC now owns 3,325,107 shares of the company’s stock valued at $26,601,000 after purchasing an additional 19,100 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Evelo Biosciences by 121.0% in the 2nd quarter. Wells Fargo & Company MN now owns 24,670 shares of the company’s stock valued at $221,000 after purchasing an additional 13,505 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Evelo Biosciences by 7.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 44,103 shares of the company’s stock valued at $397,000 after purchasing an additional 3,088 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Evelo Biosciences by 36.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 43,599 shares of the company’s stock valued at $392,000 after purchasing an additional 11,667 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Evelo Biosciences by 1.6% in the 2nd quarter. Northern Trust Corp now owns 139,200 shares of the company’s stock valued at $1,250,000 after purchasing an additional 2,202 shares in the last quarter. 86.20% of the stock is owned by institutional investors.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.
Further Reading: Why do companies issue stock splits?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.